CASE COMMENTS: MERGER CONTROL - PHARMACEUTICAL SECTOR – COMMITMENTS

Risk of monopoly : The European Commission authorizes, subject to conditions, a combination in the diagnostic systems sector (Abbott Laboratories / Alere)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. On 25 January 2017, the European Commission (the "Commission") approved the acquisition of Alere, a US company specialising in diagnostic solutions for infectious and cardio-metabolic diseases and toxicology, by Abbott Laboratories ("Abbott"), a US medical device giant listed on the New York Stock Exchange, for $5.8 billion (the "Transaction"). The closing of the Operation remains uncertain to this day,

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Clifford Chance (Paris)
  • Willkie Farr & Gallagher (Brussels)

Quotation

David Tayar, Maxime de l'Estang, Risk of monopoly : The European Commission authorizes, subject to conditions, a combination in the diagnostic systems sector (Abbott Laboratories / Alere), 25 January 2017, Concurrences N° 2-2017, Art. N° 83944, pp. 131-132

Visites 134

All reviews